The FDA has approved Somryst™ (Pear Therapeutics), a prescription digital therapeutic (PDT) intended for the treatment of patients 22 years of age and older with chronic insomnia.
The FDA has accepted for Priority Review the New Drug Application (NDA) for JZP-258 (Jazz Pharmaceuticals) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged ≥7 years with narcolepsy.
VA and DoD joint guideline addresses sleep disorders in military personnel and veterans.
Compared with placebo, cannabinoids show no improvement in pain scores in adult cancer patients.
The plaintiff’s experts testified that the twins’ genetic abnormality was not the cause of the respiratory depression, but rather a complication of the surgery.
The Food and Drug Administration (FDA) has approved Dayvigo (lemborexant; Eisai) for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
Findings show 95% increased frailty risk for co-use of sleep, pain drugs.
Sufficient sleep linked to increased odds of combined flourishing measure, individual measures
This month’s case involves a referral to another physician; a situation where it is imperative that the referring physician provide all vital information about the patient’s condition to the one who is getting the referral.
